janssen-cilag limitedhwyhosting.weebly.com/uploads/4/2/8/6/4286023/janssen...mint uk - company...

Mint UK - company report of JANSSEN-CILAG LIMITED

JANSSEN-CILAG LIMITED Identification

Registered number 01027904 DUNS number 21-731-2990Legal form Private Limited Incorporation date 19/10/1971Status Active Latest accounts 31/12/2010Global Ultimate Owner

The GUO of this controlled subsidiary is JOHNSON & JOHNSON

Previous name(s) JANSSEN PHARMACEUTICAL LIMITED until 01/01/1995 Contact address information

Address 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG England Phone 01494567567Web site janssen-cilag.co.ukE-mail [email protected] R/O address

50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG Phone 01494567567 Activities

UK SIC (2007) codesPrimary code21200 - Manufacture of pharmaceutical preparationsAll codes21200 - Manufacture of pharmaceutical preparations UK SIC (2003) codesPrimary code2442 - Manufacture of pharmaceutical preparationsAll codes2442 - Manufacture of pharmaceutical preparations Trade descriptionThe provision of the sale and distribution of pharmaceutical products. (Source: Jordans) Brand namesBinovum, Boots, Cilest, Concerta, Daktacort, Daktarin, Durogesic, Eprex, Evorel, Evra, Gyno-Daktarin, Gyno-Pevaryl, Haldol, Imodium, Leustat, Lyrinel, Micronor, Nizoral, Orap, Ortho-Creme, Ortho-Diaphragm, Ortho-Gynest, Ovex, Ovysmen, Pancrease, Pariet, Pevaryl, Rapifen, Regranex, Retin-A, Risperdal, Sporanox, Stugeron, Sublimaze, Topamax, Tramacet, Trinovum, Velcade, Vermox

Mint UK (Data update 9550 - 09/07/2012) - © BvD 11/07/2012 Page 1


Overview

It is a research-based pharmaceuticals and healthcare company. The company was formed through the merger of Janssen and Cilag in January 1995. Its corporeate headquarters is located in High Wycombe, United Kingdom.

It markets prescription medicines for a range of conditions in the areas of gastroenterology, fungal infections, women's health, mental health, neurology and pain relief. Under these areas are these brands: Binovum, Boots, Cilest, Concerta, Daktacort, Daktarin, Durogesic, Eprex, Evorel, Evra, Gyno-Daktarin, Gyno-Pevaryl, Haldol, Imodium, Leustat, Lyrinel, Micronor, Nizoral, Orap, Ortho-Creme, Ortho-Diaphragm, Ortho-Gynest, Ovex, Ovysmen, Pancrease, Pariet, Pevaryl, Rapifen, Regranex, Retin-A, Risperdal, Sporanox, Stugeron, Sublimaze, Topamax, Tramacet, Trinovum, Velcade and Vermox.

Its mission is to put patients at the heart of everything it does, and this is achieved through customer focus, personal and organizational leadership and process excellence. The company also actively operates in Austria, Belgium, Canada, the Czech Republic, Denmark, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latin America, Norway, Poland, Portugal, Slovakia, South Africa, Spain, Sweden, Switzerland, the Netherlands, Turkey and the United States. MarketLine (Datamonitor) industry profiles

Region/country Title Publication dateUnited Kingdom Facial Care 08/2011

Health Care Equipment & Supplies 07/2011OTC Pharmaceuticals 02/2012Personal Products 12/2011Skincare 08/2011

Key financials & employees

31/12/201012 months

£'000sUncons.

31/12/200912 months

£'000sUncons.

31/12/200812 months

£'000sUncons.

31/12/200712 months

£'000sUncons.

31/12/200612 months

£'000sUncons.

Turnover 271,117 293,600 235,814 254,189 241,605Profit/Loss before tax 19,530 14,843 21,045 18,058 20,176Net tangible assets (liab.) 133,446 118,342 96,591 81,131 57,705Shareholders funds 129,529 111,941 91,770 74,609 55,672Profit margin (%) 7.20 5.06 8.92 7.10 8.35Return on shareholders funds (%) 15.08 13.26 22.93 24.20 36.24Return on capital employed (%) 14.64 12.54 21.79 22.26 34.96Liquidity ratio 3.73 1.95 1.63 1.67 1.41Gearing ratio (%) 3.02 58.21 60.19 52.15 55.55Number of employees 793 826 897 836 853



GRAPHS - KEY DATA ITEMS

Turnover (£'000s) 271,117Profit/Loss before tax (£'000s) 19,530Number of employees 793

70

75

80

85

90

95

100

105

110

115

120

125%

20102009200820072006

Shareholders funds (£'000s) 129,529Net tangible assets (liab.) (£'000s) 133,446

100

120

140

160

180

200

220

240%

20102009200820072006

Detailed financials

31/12/201012 months

£'000sUncons.

31/12/200912 months

£'000sUncons.

31/12/200812 months

£'000sUncons.

31/12/200712 months

£'000sUncons.

31/12/200612 months

£'000sUncons.

PROFIT & LOSS ACCOUNT

Turnover 271,117 293,600 235,814 254,189 241,605UK turnover 235,814Export turnover

Cost of salesExceptional items pre GPOther income pre GPGross profitAdministration expenses -256,866 -372,621 -312,973 -323,530 -270,078Other operating income pre OP 4,802Exceptional items pre OPOperating profit 19,053 -79,021 -77,159 -69,341 -28,473Other income 93,943 98,373 87,460 48,730Total other income & int received 538 93,943 98,373 87,460 48,730Exceptional itemsProfit (loss) on sale of operationsCosts of reorganisationProfit (loss) on disposalOther exceptional items

Profit (loss) before interest paid 19,591 14,922 21,214 18,119 20,257Interest received 538Interest paid -61 -79 -169 -61 -81Paid to bank -61Paid on hire purchasePaid on leasingOther interest paid

Net interest 477 -79 -169 -61 -81Profit (loss) before tax 19,530 14,843 21,045 18,058 20,176Taxation -1,797 3,224 -4,613 -559 4,504Profit (loss) after tax 17,733 18,067 16,432 17,499 24,680Extraordinary itemsMinority interestsProfit (loss) for period 17,733 18,067 16,432 17,499 24,680



Detailed financials31/12/201012 months

£'000sUncons.

31/12/200912 months

£'000sUncons.

31/12/200812 months

£'000sUncons.

31/12/200712 months

£'000sUncons.

31/12/200612 months

£'000sUncons.

DividendsRetained profit (loss) 17,733 18,067 16,432 17,499 24,680

Depreciation 2,655 2,477 2,534 2,815 2,842Depreciation owned assetsDepreciation other assets 2,655Impairment tangibles

Audit fee 62 64 65 65 57Non-audit fee 72 61Tax adviceNon-tax advisory servicesOther auditors servicesNon-audit fees paid to other auditors

Amortisation of goodwillAmortisationWrite back of goodwill

Total operating lease rentals 5,002Hire of plant & machinery 1,582Land & building or property rents & other 3,420

Research & development 39,392Foreign exchange gains/lossesRemuneration 68,257 92,292 71,040 64,409 60,919Wages & salaries 53,917 55,643 49,669 51,777 48,218Social security costs 4,985 4,551 4,860 4,627Pension costs 31,664 16,820 7,772 8,074Other staff costs 14,340

Directors' remuneration 2,093 774 869 775 964Directors' fees 2,093 775 964Pension contributionOther emoluments

Highest paid director 1,632 445 613 520 527EBITDA 21,708 -76,544 -74,625 -66,526 -25,631

Number of employees 793 826 897 836 853




£'000sUncons.

31/12/200912 months

£'000sUncons.

31/12/200812 months

£'000sUncons.

31/12/200712 months

£'000sUncons.

31/12/200612 months

£'000sUncons.

BALANCE SHEET

Fixed assets Tangible assets 7,146 8,385 11,163 11,054 10,881Land & buildings 213 249 3,374 4,572Freehold land 213Leasehold land

Fixtures & fittings 0 8,081 7,713 6,081Plant & vehicles 35 55 76 228PlantVehicles 35

Other fixed assets 6,898 0 0 0Intangible assetsInvestments 200 200 200 200 200Fixed assets 7,346 8,585 11,363 11,254 11,081

Current assets Stock & W.I.P. 28,584 26,203 23,617 19,773 20,327Stock 26,203 23,617 19,773 20,327 W.I.P. 0 0 0 0Finished goods 28,584

Trade debtors 26,570 27,704 39,165 29,387 25,368Bank & deposits 14,125 100,297 80,607 64,304 44,220Other current assets 92,553 43,696 39,797 30,993 20,990Group loans (asset) 86,356 36,446 31,657 25,019 17,118Directors loans (asset) 0 0 0 0 0Other debtors 1,179 7,250 8,140 5,974 3,872Prepayments 834Deferred taxation 4,184

InvestmentsCurrent assets 161,832 197,900 183,186 144,457 110,905

Current liabilities Trade creditors -11,229 -12,178 -19,756 -14,049 -8,505Short term loans & overdrafts -58,757 -50,416 -32,390 -28,892Bank overdrafts 0 0 0 0Group loans (short t.) -58,757 -50,416 -32,390 -28,892Director loans (short t.) 0 0 0 0Hire purch. & leas. (short t.) 0 0 0 0Hire purchase (short t.)Leasing (short t.)

Preference SharesOther short term loans 0 0 0 0

Total other current liabilities -24,503 -17,208 -27,786 -28,141 -26,884Corporation tax -2,666 -843 -3,192 -7,405 -4,707Dividends 0 0 0 0 0Accruals & def. inc. (short t.) -15,058 -10,574 -20,096 -14,566 -17,544Social securities & V.A.T. -6,779 -5,791 0 0 0Other current liabilities 0 0 -4,498 -6,170 -4,633

Current liabilities -35,732 -88,143 -97,958 -74,580 -64,281

Net current assets (liab.) 126,100 109,757 85,228 69,877 46,624Net tangible assets (liab.) 133,446 118,342 96,591 81,131 57,705Working capital 126,100 109,757 85,228 69,877 46,624Total assets 169,178 206,485 194,549 155,711 121,986Total assets less cur. liab. 133,446 118,342 96,591 81,131 57,705

Long term liabilities Long term debtGroup loans (long t.)Director loans (long t.)Hire purch. & leas. (long t.)Hire purchase (long t.)Leasing (long t.)

Preference Shares




£'000sUncons.

31/12/200912 months

£'000sUncons.

31/12/200812 months

£'000sUncons.

31/12/200712 months

£'000sUncons.

31/12/200612 months

£'000sUncons.

Other long term loansTotal other long term liab. -2,760Accruals & def. inc. (long t.) 0 0 0 0 0Other long term liab. -2,760 0 0 0 0Provisions for other liab. 0 -6,401 -4,821 -6,522 -2,033Deferred taxOther provisions -6,401 -4,821 -6,522 -2,033

Pension liabilities -1,157Balance sheet minoritiesLong term liabilities -3,917 -6,401 -4,821 -6,522 -2,033

Total assets less liabilities 129,529 111,941 91,770 74,609 55,672

Shareholders' funds Issued capital 240 240 240 240 240Ordinary shares 240Preference sharesOther shares

Total reserves 129,289 111,701 91,530 74,369 55,432Share premium account 2,910 2,910 2,910 2,910 2,910Revaluation reserves 0 0 0 0 0Profit (loss) account 116,711 98,978 80,912 71,459 52,522Other reserves 9,668 9,813 7,708 0 0Shareholders' funds 129,529 111,941 91,770 74,609 55,672

31/12/201012 months

£'000sUncons.

31/12/200912 months

£'000sUncons.

31/12/200812 months

£'000sUncons.

31/12/200712 months

£'000sUncons.

31/12/200612 months

£'000sUncons.

CASH FLOW STATEMENT

Net cash in(out)flow operat. activ.Net cash in(out)flow ret. on invest.TaxationNet cash out(in)flow investing activ.Capital expend. & financial invest.Acquisitions & disposalsEquity dividends paidManagement of liquid resourcesNet cash out(in)flow from financingNet (de)increase in cash & equiv.



Detailed financials31/12/2010

Uncons.31/12/2009

Uncons.31/12/2008

Uncons.31/12/2007

Uncons.31/12/2006

Uncons.RATIOS

BALANCE SHEET RATIOS Current ratio 4.53 2.25 1.87 1.94 1.73Liquidity ratio 3.73 1.95 1.63 1.67 1.41Shareholders liquidity ratio 33.07 17.49 19.04 11.44 27.38Solvency ratio (%) 76.56 54.21 47.17 47.92 45.64Asset coverGearing (%) 3.02 58.21 60.19 52.15 55.55Shareholders funds per empl. (unit) 163,340 135,522 102,308 89,245 65,266Working capital per employee (unit) 159,016 132,878 95,014 83,585 54,659Total assets per employee (unit) 213,339 249,982 216,889 186,257 143,008

PROFITABILITY RATIOS Profit margin (%) 7.20 5.06 8.92 7.10 8.35Return on shareholders funds (%) 15.08 13.26 22.93 24.20 36.24Return on capital employed (%) 14.64 12.54 21.79 22.26 34.96Return on total assets (%) 11.54 7.19 10.82 11.60 16.54Interest cover 321.16 188.89 125.53 297.03 250.09Stock turnover 9.48 11.20 9.98 12.86 11.89Debtors turnover 10.20 10.60 6.02 8.65 9.52Debtor collection (days) 35.77 34.44 60.62 42.20 38.32Creditors payment (days) 15.12 15.14 30.58 20.17 12.85Net assets turnover 2.03 2.48 2.44 3.13 4.19Fixed assets turnover 36.91 34.20 20.75 22.59 21.80Salaries/turnover (%) 25.18 31.43 30.13 25.34 25.21Gross margin (%)Berry ratioEBIT margin (%) 7.03 -26.91 -32.72 -27.28 -11.78EBITDA margin (%)Turnover per employee (unit) 341,888 355,448 262,892 304,054 283,242Average remun. per employee (unit) 86,074 111,734 79,197 77,044 71,417Profit per employee (unit) 24,628 17,970 23,462 21,600 23,653



Detailed financials2010-09 2009-08 2008-07 2007-06 2006-05

TRENDS & CHANGES

BALANCE SHEET TRENDS & CHANGES

Trends (%) Fixed assets -14.43 -24.45 0.97 1.56 -13.40Current assets -18.23 8.03 26.81 30.25 -1.71Stock 9.09 10.95 19.44 -2.73 -5.68Debtors -4.09 -29.26 33.27 15.84 -40.65Total assets -18.07 6.14 24.94 27.65 -2.90Current liabilities -59.46 -10.02 31.35 16.02 -29.53Creditors -7.79 -38.36 40.62 65.19 -59.31Loans/Overdraft 16.54 55.65 12.11 -8.72Long term liabilities -38.81 32.77 -26.08 220.81 -78.39

Changes (£'000s) Fixed assets -1,239 -2,778 109 173 -1,714Current assets -36,068 14,714 38,729 33,552 -1,928Stock 2,381 2,586 3,844 -554 -1,225Debtors -1,134 -11,461 9,778 4,019 -17,374Total assets -37,307 11,936 38,838 33,725 -3,642Current liabilities -52,411 -9,815 23,378 10,299 -26,940Creditors -949 -7,578 5,707 5,544 -12,396Loans/Overdraft 8,341 18,026 3,498 -2,759Long term liabilities -2,484 1,580 -1,701 4,489 -7,375

PROFITABILITY TRENDS & CHANGES

Trends (%) Turnover -7.66 24.50 -7.23 5.21 3.98Profit before taxation 31.58 -29.47 16.54 -10.50 2.22Interest paid -22.78 -53.25 177.05 -24.69 -74.37Number of employees -4.00 -7.92 7.30 -1.99 -3.94

Changes Turnover (£'000s) -22,483 57,786 -18,375 12,584 9,238Profit before taxation (£'000s) 4,687 -6,202 2,987 -2,118 439Interest paid (£'000s) -18 -90 108 -20 -235Number of employees -33 -71 61 -17 -35

Peer report

Companies closest to the subject company selected according to: Turnover Size of the peer group: 10 Selected reference year: Last avail. year

Balance sheet and P/L accounts items Company name Last

avail. year

Turnover£'000s

Profit/Lossbefore tax

£'000s

Net tangibleassets (liab.)

£'000s

Shareholdersfunds

£'000s

Number ofemployees

Average LY 217,948 22,147 90,276 80,883 672 DECHRA PHARMACEUTICALS PLC

2011 389,237 (1) 18,514 (4) 56,318 (6) 98,333 (4) 1,005 (2)

NOVARTIS VACCINES AND DIAGNOSTICS LIMITED

2010 356,100 (2) 127,700 (1) 399,800 (1) 365,300 (1) 758 (5)

TEVA UK LIMITED 2010 285,068 (3) 8,750 (7) 5,419 (11) -7,813 (11) 678 (6)JANSSEN-CILAG LIMITED

2010 271,117 (4) 19,530 (3) 133,446 (3) 129,529 (2) 793 (4)

NAPP PHARMACEUTICAL HOLDINGS LIMITED

2010 253,237 (5) 37,493 (2) 137,910 (2) 110,943 (3) 855 (3)

BCM LIMITED 2011 187,500 (6) -12,100 (11) 30,500 (9) -300 (10) 266 (11)ACTAVIS UK LIMITED 2011 164,723 (7) 10,962 (6) 33,178 (8) 22,139 (8) 620 (7)



Peer reportNORBROOK LABORATORIES LIMITED

2011 160,889 (8) 16,776 (5) 87,009 (4) 64,443 (5) 1,424 (1)

ORGANON LABORATORIES LIMITED

2010 129,436 (9) 3,499 (10) 60,394 (5) 60,394 (6) 319 (9)

NAPP PHARMACEUTICALS LIMITED

2010 108,009 (10) 6,269 (8) 12,162 (10) 12,096 (9) 274 (10)

BARD PHARMACEUTICALS LIMITED

2010 92,110 (11) 6,229 (9) 36,897 (7) 34,649 (7) 403 (8)

Ratios Company name Last

avail. year

Profit margin(%)

Return onshareh. funds

(%)

Return oncapital

employed (%)

Liquidityratio

Gearing ratio(%)

Average LY 8.33 28.20 18.98 1.78 63.47 DECHRA PHARMACEUTICALS PLC

2011 4.76 (8) 18.83 (6) 10.21 (9) 1.09 (6) 93.14 (4)

NOVARTIS VACCINES AND DIAGNOSTICS LIMITED

2010 35.86 (1) 34.96 (3) 31.94 (4) 4.16 (1) 18.81 (6)

TEVA UK LIMITED 2010 3.07 (9) 40.95 (2) 0.55 (10)JANSSEN-CILAG LIMITED

2010 7.20 (4) 15.08 (8) 14.64 (8) 3.73 (2) 3.02 (9)

NAPP PHARMACEUTICAL HOLDINGS LIMITED

2010 14.81 (2) 33.79 (4) 26.34 (5) 3.44 (3) 30.10 (5)

BCM LIMITED 2011 -6.45 (11) -40.60 (11) 0.75 (7)ACTAVIS UK LIMITED 2011 6.65 (6) 49.51 (2) 31.97 (3) 0.60 (9) 130.16 (2)NORBROOK LABORATORIES LIMITED

2011 10.43 (3) 26.03 (5) 19.14 (6) 0.61 (8) 119.00 (3)

ORGANON LABORATORIES LIMITED

2010 2.70 (10) 5.79 (9) 5.79 (10) 2.82 (4) 17.39 (7)

NAPP PHARMACEUTICALS LIMITED

2010 5.80 (7) 51.83 (1) 51.55 (1) 1.40 (5) 152.51 (1)

BARD PHARMACEUTICALS LIMITED

2010 6.76 (5) 17.98 (7) 16.88 (7) 0.48 (11) 7.13 (8)

The figures displayed between brackets show the position of the company within the group



Peer report graph

Breakdown according to: Profit/Loss before tax Selected reference year: Last avail. yr

Variable: Profit/Loss before tax (100% = 255,722,000 £) Year: Last avail. yr

ORGANON LABORATORIESLIMITED(1.37%)

BARD PHARMACEUTICALSLIMITED(2.44%)

NAPP PHARMACEUTICALSLIMITED(2.45%)

TEVA UK LIMITED(3.42%)

ACTAVIS UK LIMITED(4.29%)

NORBROOK LABORATORIESLIMITED(6.56%)

NOVARTIS VACCINES ANDDIAGNOSTICS LIMITED(49.94%)

NAPP PHARMACEUTICALHOLDINGS LIMITED

(14.66%)

JANSSEN-CILAG LIMITED(7.64%)

DECHRA PHARMACEUTICALSPLC

(7.24%)

Company(ies) not included in the pie chart Variable : Profit/Loss before tax (£) Year: Last avail. yr BCM LIMITED -12,100,000 Credit score & rating

Current QuiScore 92 (02/01/2011) High Risk Secure

Previous QuiScore 93 (02/12/2009) High Risk Secure

QuiRating (£) 999,999 Proper assessment of this company will require consideration of the ultimate owner : JOHNSON & JOHNSON Historical credit score & rating

Current 31/12/2010 31/12/2009 31/12/2008 31/12/2007 31/12/2006

QuiScore 92 92 93 89 89 90QuiScore comment

Secure Secure Secure Secure Secure Secure

QuiRating (GBP) 999,999 999,999 999,999 999,999 999,999 999,999 Mortgage data

REGISTRATION Status SatisfiedFully satisfied 01/05/2003Registered 01/06/2002Number 1Created 31/05/2002



Mortgage data DETAILS Mortgage Description TENANCY AGREEMENTCharge Status SatisfiedPerson Entitled JOHN EDWARD WOODS AND JUDITH LYNDA WOODSAmount Secured ALL MONIES DUE OR TO BECOME DUE FROM THECOMPANY TO THE

CHARGEE UNDER THE TERMSOF THE AFOREMENTIONED INSTRUMENT CREATING OR EVIDENCING THE CHARGE

Short Particulars THE SUM OF £15,000 AND ACCRUED INTERESTHELD ON DEPOSIT AS SECURITY TOWARDS THEPERFORMANCE OF THE COMPANY'S OBLIGATIONSAND LIABILITIES UNDER THE TERMS OF THETENANCY AGREEMENT MADE BETWEEN THE COMPANY AND THE CHARGEES

Current directors

Name Role (Occupation) Appointment

date 1. Dr Peter Mark Fraser Barnes Director (occupation: Business

Executive)05/02/2007

2. Mr. Harjinder Nijjar Director (occupation: Finance Director)

28/04/2005

3. Mr. Cesar Rodriguez Valdajos Director (occupation: Business Executive)

15/08/2011

4. Mrs. Barbara Susan Butterworth

Company Secretary 10/01/1992

Previous directors

Name Role (Occupation) Appointment

dateResignationdate

1. Mr. Jesus Maria Caintos Fernandez

Director (occupation: Business Executive)

10/12/1992 28/01/1999

2. Dr Maurice Cohen Director (occupation: Business Executive)

10/01/1992 11/03/1992

3. Dr Robert John Donnelly Director (occupation: Medical Director)

12/01/1995 05/05/2006

4. Mr. David John Drickwood Director (occupation: Managing Director)

07/07/1994 26/12/1999

5. Mr. Bruce Michael Goodwin Director (occupation: Finance Director)

01/02/2000 26/05/2003

6. Mr. Thomas Nicholas Graney Director (occupation: Business Executive)

09/06/2003 28/04/2005

7. Mr. David Cooper Jackson Director (occupation: Finance Director)

07/12/1994 15/10/1997

8. Dr Paul Janssen Director (occupation: Business Executive)

10/01/1992 22/06/1992

9. Mr. Philip Henry Keller Director (occupation: Business Executive)

10/06/1998 01/01/2000

10. Mr. John McDonald Director (occupation: Managing Director)

01/01/2000 31/01/2008

11. Mr. Rodrigo Resende San Martin

Director (occupation: Business Executive)

01/01/2010 15/06/2011

12. Sunangal Ajit Shetty Director (occupation: Executive Vice President)

13/09/1995 26/05/2003

13. Mr. Michael Emmerson Snaith Director (occupation: Business Executive)

10/01/1992 07/07/1994

14. Mr. Silvano Valentino Tanca Director (occupation: Business Executive)

22/06/1992 20/12/2001

15. Mr. Christian Verbeeck Director (occupation: Business Executive)

28/01/1999 26/05/2003

16. Mr. Guido Alice Godfried Vercauteren

Director 10/01/1992 10/12/1992

17. Mr. Martin Peter Wakeford Director (occupation: Business Executive)

08/12/1989 08/12/1989

18. Mr. Robert Nathan Wilson Director (occupation: Business Executive)

08/12/1989 08/12/1989

19. Dr Stephen James Wooding Director (occupation: Business Executive)

16/01/2009 23/12/2009



Key contacts

Contacts at main address

Name Position Function 1. Miss Peter M Barnes Director Senior contact 2. Mr. Harjinder Nijjar Finance Director Financial contact 3. Mr. Harjinder Nijjar Director Financial Director 4. Dr Stephen Wooding Director PA to Senior Decisionmaker The purpose of the contact data section is to provide the names of individuals in key areas of a business who are located at any of the addresses linked to the displayed company. However, there is no guarantee that there is any legal relationship between each person displayed and the company report they appear on. LinkedIn contacts

The corporate group

GUO: JOHNSON & JOHNSON (US) The companies underlined and displayed in bold black are available on Mint UK.The companies underlined and displayed in grey are available on Mint Global. Subsidiary name Source

dateOp. rev.

£'000sTot. assets

£'000sEmployees Country Postcode

areaNACE

Rev. 2.01.

JANSSEN CILAG SA 09/2011 497,000 272,000 550 ES 4646

1.1.

JANSSEN-PHARMA SL 09/2011 7,000 1,000 78 ES 46462.

JOHNSON & JOHNSON HELLAS S.A.

04/2012 151,000 228,000 430 GR 2042

2.1.

JOHNSON & JOHNSON ELLAS CONSUMER S.A.

04/2012 n.a. n.a. n.a. n.a.

3.

JOHNSON & JOHNSON HOLDING GMBH

01/2012 n.a. 1,632,000 n.a. DE 7010

3.1.

CORDIS MEDIZINISCHE APPARATE GMBH

03/2012 77,000 24,000 84 DE 4646

3.2.

DEPUY ORTHOPÄDIE GMBH

11/2011 113,000 31,000 174 DE 4646

3.3.

JANSSEN-CILAG GMBH 11/2011 415,000 206,000 932 DE 20003.3.1. I3G INSTITUT FÜR

INNOVATION UND INTEGRATION IM GESUNDHEITSWESEN GMBH

10/2011 n.a. n.a. 1 DE 4646

3.3.1.1. CARE4S GMBH 05/2012 n.a. n.a. n.a. DE3.3.2. ORTHO-CLINICAL

DIAGNOSTICS GMBH11/2011 60,000 56,000 210 DE 3250

3.4.

JOHNSON & JOHNSON FINANCIAL SERVICES GMBH

11/2011 38,000 115,000 4 DE 7729

3.5.

JOHNSON & JOHNSON GMBH

06/2011 215,000 192,000 751 DE 2041

3.5.1. DR. CARL HAHN GMBH 11/2011 n.a.


The corporate group Subsidiary name Source

dateOp. rev.

£'000sTot. assets


areaNACE

Rev. 2.06.

JANSSEN-CILAG PHARMACEUTICAL S.A.C.I.

03/2012 110,000 143,000 200 GR 4646

7.

ALZA CORP 04/2012 663,000 1,958,000 2,442 US 21207.1.

ALZA HOLDINGS IRELAND LIMITED

05/2012 n.a.



dateOp. rev.

£'000sTot. assets


areaNACE

Rev. 2.011.1.7. MENTOR

BIOPOLYMERS LIMITED

05/2012 n.a. 1,493 n.a. GB RG40 3250

11.1.8. MICRUS ENDOVASCULAR UK LIMITED

08/2011 3,450 1,282 6 GB RG40 3250

11.1.9. ORTHO-CLINICAL DIAGNOSTICS

05/2012 172,172 181,321 496 GB HP12 2110

11.1.10. DEPUY UK HOLDINGS LIMITED

10/2011 n.a. 124,524 n.a. GB LS11 7010

11.1.10.1. DEPUY INTERNATIONAL (HOLDINGS) LIMITED

05/2012 n.a. 193,942 n.a. GB LS11 7010

11.1.10.2. ORTHOGENESIS LIMITED

05/2012 n.a. 0 n.a. GB LS11

11.1.11. MENTOR WORLDWIDE LLC

05/2012 73,000 n.a. 1,200 US 3250

11.1.11.1. MENTOR AESTHETICS EUROPE B.V.

02/2012 n.a. 3,000 1 NL 4646

11.1.11.2. MENTOR BENELUX B.V. 02/2012 n.a.



dateOp. rev.

£'000sTot. assets


areaNACE

Rev. 2.011.1.11.25. MENTOR TEXAS GP LLC 03/2008 n.a. n.a. n.a. US11.1.11.26. PEROUSE PLASTIE

GERMANY03/2008 n.a. n.a. n.a. DE

11.1.11.27. PP SUD LTD 03/2008 n.a. n.a. 55 MU 201411.1.11.28. MENTOR

CORPORATION03/2012 208,000 n.a. 476 US 3250

11.1.11.28.1. MENTOR MEDICAL SYSTEMS B.V.

02/2012 12,000 42,000 196 NL 3250

11.1.11.29. MENTOR MEDICAL SYSTEMS (CANADA) INC

09/2010 2,000 n.a. 23 CA 4690

11.1.11.30. MENTOR TEXAS LP 07/2011 13,000 n.a. 350 US 325011.1.12. MENTOR MEDICAL

SYSTEMS LIMITED05/2012 7,000 1,522 23 GB RG14 8299

11.1.13. JOHNSON & JOHNSON GROUP HOLDINGS GMBH

06/2011 n.a. 1,676,000 n.a. DE 7010

11.2.

JEVCO LIMITED 11/2011 n.a. 1,795 n.a. GB EH54 721912.

MAPLE MERGER SUB INC 01/2009 n.a. n.a. n.a. US

13.

JOHNSON & JOHNSON GESELLSCHAFT M.B.H.

03/2012 46,000 n.a. 50 AT 4645

14.

CONOR MEDSYSTEMS LLC 10/2011 n.a. n.a. n.a. US14.1.

CONOR MEDSYSTEMS INTERNATIONAL LIMITED

05/2012 n.a. n.a. n.a. IE 7010

14.1.1. CONOR MEDSYSTEMS IRELAND LIMITED

05/2012 n.a. 1,000 n.a. IE 4774

15.

JNJ INTERNATIONAL INVESTMENT LLC

11/2011 n.a. n.a. n.a. US

15.1.

JANSSEN PHARMACEUTICAL

05/2012 4,758,000 6,653,000 7,214 IE

15.1.1. ROSSCROWN DEVELOPMENTS LIMITED

05/2010 n.a. 4,000 n.a. IE 6499

15.1.2. DEPUY (IRELAND) 05/2012 n.a. n.a. n.a. IE 325015.1.2.1. FINSBURY

ORTHOPAEDICS LIMITED

11/2011 n.a. 111 n.a. GB KT22

15.1.2.1.1. FINSBURY (DEVELOPMENT) LIMITED

05/2012 1,431 1,327 19 GB KT22 7219

15.1.2.1.2. FINSBURY (INSTRUMENTS) LIMITED

05/2012 26,981 13,099 78 GB KT22 3250

15.1.2.1.2.1. FINSBURY GMBH 12/2011 n.a.



dateOp. rev.

£'000sTot. assets


areaNACE

Rev. 2.015.1.3.4. LATAM PROPERTIES

HOLDINGS05/2012 n.a. 700,000 n.a. IE 6499

15.1.3.4.1. LATAM INTERNATIONAL INVESTMENT COMPANY

05/2012 n.a. 728,000 n.a. IE 6499

15.1.3.4.1.1. JOHNSON & JOHNSON DO BRASIL INDÚSTRIA E COMÉRCIO DE PRODUTOS PARA SAÚDE LTDA.

10/2010 n.a. n.a. 4,000 BR 3250

15.1.3.4.1.1.1. JANSSEN-CILAG FARMACÊUTICA LTDA.

03/2011 146,000 n.a. 800 BR 2120

15.1.3.4.1.1.2. JOHNSON & JOHNSON INDUSTRIAL LTDA.

03/2012 n.a. n.a. 1,200 BR 1722

15.1.3.5. JOHNSON & JOHNSON DE ARGENTINA S.A.C.E.I.

07/2011 44,000 31,000 298 AR 2042

15.1.3.6. JOHNSON & JOHNSON EGÉSZSÉGÜGYI ÉS BABAÁPOLÁSI TERMÉKEKET GYÁRTÓ ÉS FORGALMAZÓ KORLÁTOLT FELELOSSÉGU

11/2008 38,000 19,000 151 HU 4645

15.1.4. JOHNSON & JOHNSON EUROPEAN TREASURY COMPANY

05/2012



dateOp. rev.

£'000sTot. assets


areaNACE

Rev. 2.023.2.

GLOSTER EUROPE 07/2010 1,000 1,000 12 FR 3250

23.3.

JANSSEN CILAG 07/2010 838,000 302,000 1,197 FR 464623.3.1. ORTHOCLINICAL

DIAGNOSTICS FRANCE06/2012 415,000 157,000 226 FR 4646

23.3.2. A CHACUN SON EVEREST

06/2012 n.a. n.a. n.a. FR 9499

23.4.

JOHNSON & JOHNSON CONSUMER HOLDINGS FRANCE

07/2010 5,000 328,000 550 FR 6420

23.4.1. JOHNSON & JOHNSON SANTE BEAUTE FRANCE

09/2010 504,000 370,000 966 FR 4645

23.4.2. VANIA EXPANSION 09/2010 7,000 66,000 50 FR 464623.5.

DEPUY ORTHOPEDIE SA 07/2010 n.a. 27,000 n.a. FR 6420

23.5.1. DEPUY FRANCE 02/2011 54,000 24,000 130 FR 464623.5.1.1. PAMERLAND 02/2011 1,000



dateOp. rev.

£'000sTot. assets


areaNACE

Rev. 2.034.11.1.2.1. BERNA BIOTECH

KOREA CORP.12/2009 139,000 195,000 274 KR 2120

34.11.1.2.2. CRUCELL BIOLOGICS INC.

12/2009 n.a. n.a. n.a. US

34.11.1.2.3. CRUCELL HOLDING INC.

12/2009 n.a. n.a. n.a. US

34.11.1.2.4. CRUCELL HOLLAND B.V.

06/2012 3,000 19,000 120 NL 7219

34.11.1.2.4.1. CHROMAGENICS B.V. 06/2012 n.a. 1,000 6 NL 721934.11.1.2.4.2. U-BISYS B.V. 06/2012 n.a. 1,000 n.a. NL 721934.11.1.2.4.3. CRUCELL UK

LIMITED01/2012 3,391 2,343 35 GB BD17 2110

34.11.1.2.5. CRUCELL SWEDEN AB 12/2009 34,000 38,000 111 SE 212034.11.1.2.6. CRUCELL

SWITZERLAND AG06/2011 69,000 n.a. 400 CH 7219

34.11.1.2.6.1. BERNA BIOTECH ITALY SRL

06/2011 n.a. n.a. n.a. IT

34.11.1.2.6.2. BERNA RHEIN B.V. 06/2011 n.a. 65,000 1 NL 642034.11.1.2.6.3. CRUCELL SPAIN SA 09/2011 20,000 27,000 70 ES 212034.11.1.2.7. BERNA RHEIN B.V. 06/2012 n.a. 65,000 1 NL 642034.11.1.2.8. CHROMAGENICS B.V. 12/2009 n.a. 1,000 6 NL 721934.11.1.2.9. CRUCELL ITALY

SOCIETA A RESPONSABILITA LIMITATA

12/2009 12,000 13,000 17 IT 2100

34.11.1.2.10. CRUCELL SPAIN SA 12/2009 20,000 27,000 70 ES 212034.11.1.2.11. CRUCELL UK

LIMITED12/2009 3,391 2,343 35 GB BD17 2110

34.11.1.2.12. U-BISYS B.V. 12/2009 n.a. 1,000 n.a. NL 721934.11.1.3. JANSSEN BIOLOGICS

B.V.06/2012 57,000 79,000 500 NL 2120

34.11.1.4. JANSSEN-CILAG B.V. 06/2012 n.a. n.a. 221 NL 464634.11.1.4.1. JOHNSON & JOHNSON

CONSUMER B.V.06/2012 n.a. n.a. 54 NL 4646

34.11.1.5. JOHNSON & JOHNSON MEDICAL B.V.

06/2012 n.a. n.a. 181 NL 4646

34.11.1.6. TECHNICARE B.V. 06/2012 n.a. 2,000 n.a. NL 642034.11.2. CRUCELL N.V. 04/2011 312,000 826,000 1,300 NL 721134.12.

DEPUY SPINE SÀRL 06/2011 241,000 n.a. 44 CH 7219

34.13.

CODMAN NEURO SCIENCES SÀRL

06/2011 3,000 n.a. 8 CH 7219

34.14.

JOHNSON & JOHNSON SWISS FINANCE COMPANY LIMITED

05/2012



dateOp. rev.

£'000sTot. assets


areaNACE

Rev. 2.036.1.

JANSSEN BIOLOGICS (IRELAND)

05/2012 n.a. 181,000 n.a. IE 2120

37.

CODMAN & SHURTLEFF INC

01/2011



dateOp. rev.

£'000sTot. assets


areaNACE

Rev. 2.074.

J&J HOLDINGS (NEVADA) INC.

01/2011 n.a. n.a. n.a. US

75.

J-C HEALTHCARE LTD 01/2011 n.a. n.a. n.a. IL76.

J.C. GENERAL SERVICES 01/2011 76,000 3,615,000 94 BE 7010

77.

JANSSEN - CILAG FARMACEUTICA, LDA

01/2011 69,000 25,000 114 PT 4646

78.

JANSSEN ALZHEIMER IMMUNOTHERAPY

01/2011 n.a. n.a. n.a. IE 7219

79.

JANSSEN ALZHEIMER IMMUNOTHERAPY RESEARCH AND DEVELOPMENT, LLC

01/2011 6,000 n.a. 100 US 7211

80.

JANSSEN BIOLOGICS (IRELAND)

01/2011 n.a. 181,000 n.a. IE 2120

81.

JANSSEN BIOLOGICS B.V. 01/2011 57,000 79,000 500 NL 212082.

JANSSEN CILAG 01/2011 838,000 302,000 1,197 FR 4646

83.

JANSSEN CILAG FARMACEUTICA S.A.

01/2011 n.a. n.a. n.a. AR

84.

JANSSEN CILAG SPA 01/2011 470,000 326,000 958 IT 464685.

JANSSEN DE MEXICO, S DE RL DE CV

01/2011 n.a. n.a. n.a. MX

86.

JANSSEN GLOBAL SERVICES, LLC

01/2011 n.a. n.a. n.a. US

87.

JANSSEN INC 01/2011 62,000 n.a. 600 CA 464588.

JANSSEN INFECTIOUS DISEASES-DIAGNOSTICS

01/2011 106,000 43,000 373 BE 7219

89.

JANSSEN ORTHO LLC 01/2011 n.a. n.a. n.a. US90.

JANSSEN PHARMACEUTICA

01/2011 3,357,000 5,555,000 3,713 BE 2120

90.1.

OMRIX BIOPHARMACEUTICALS LTD

12/2010 n.a. n.a. n.a. IL

90.2.

PREDSTAVITELSTVO KOMPANII YANSSEN FARMATSEVTIKA NV (BELGIYA) G. MOSCOW

04/2012 n.a. n.a. n.a. RU 7311

90.3.

JANSSEN-CILAG 12/2010 116,000 72,000 173 BE 464690.3.1. ORTHO - CLINICAL

DIAGNOSTICS12/2010 29,000 31,000 105 BE 3250

90.4.

ORTHO - CLINICAL DIAGNOSTICS

12/2010 29,000 31,000 105 BE 3250

90.5.

JANSSEN - CILAG INTERNATIONAL

12/2010



dateOp. rev.

£'000sTot. assets


areaNACE

Rev. 2.0101.

JANSSEN-CILAG GMBH 01/2011 415,000 206,000 932 DE 2000

102.

JANSSEN-CILAG LTD 01/2011 62,000 23,000 n.a. TH 2120103.

JANSSEN-CILAG OY 01/2011 92,000 45,000 124 FI 4646

104.

JANSSEN-CILAG PTY LIMITED

01/2011 n.a. n.a. n.a. AU

105.

JANSSEN-CILAG, S.R.O. 01/2011 44,000 15,000 75 CZ 7310106.

JHC NEDERLAND B.V. 01/2011 664,000 769,000 1,710 NL 4646

107.

JJHC LLC 01/2011 n.a. n.a. n.a. US108.

JOHNSON & JOHNSON ( PHILIPPINES), INC.

01/2011 83,000 24,000 n.a. PH 2042

109.

JOHNSON & JOHNSON (2004) LIMITED

01/2011 n.a. n.a. n.a. GB

110.

JOHNSON & JOHNSON (CHINA) INVESTMENT CO LTD

01/2011 n.a. n.a. n.a. CN

110.1.

BEIJING DABAO COSMETICS CO., LTD.

07/2008 71,000 82,000 1,136 CN 2042

111.

JOHNSON & JOHNSON (CHINA) LTD

01/2011 n.a. n.a. n.a. CN

112.

JOHNSON & JOHNSON (HONG KONG) LIMITED

01/2011 5,174,000 n.a. 150 HK 4646

113.

JOHNSON & JOHNSON (MIDDLE EAST) INC

01/2011 n.a. n.a. 2 US 4645

114.

JOHNSON & JOHNSON (THAILAND) LTD

01/2011 98,000 85,000 n.a. TH 4690

115.

JOHNSON & JOHNSON AB 01/2011 191,000 82,000 310 SE 4646115.1.

JOHNSON & JOHNSON, FILIAL AF JOHNSON & JOHNSON AB, SVERIGE

02/2012 n.a. n.a. n.a. DK 4646

115.2.

UAB JOHNSON & JOHNSON

03/2009 12,000 8,000 32 LT 4646

115.3.

UAB JOHNSON & JOHNSON (LITHUANIA)

07/2011 n.a. n.a. n.a. LT

116.

JOHNSON & JOHNSON CONSUMER B.V.

01/2011 n.a. n.a. 54 NL 4646

117.

JOHNSON & JOHNSON CONSUMER COMPANIES, INC

01/2011 29,336,000 33,698,000 n.a. US 3250

118.

JOHNSON & JOHNSON CONSUMER HOLDINGS FRANCE

01/2011 5,000 328,000 550 FR 6420

119.

JOHNSON & JOHNSON CONSUMER SERVICES EAME LTD

01/2011 110,182 73,646 256 GB SL6 8299

120.

JOHNSON & JOHNSON DE ARGENTINA S.A.C.E.I.

01/2011 44,000 31,000 298 AR 2042

121.

JOHNSON & JOHNSON DE VENEZUELA, S.A

01/2011 n.a. n.a. 300 VE 2041

122.

JOHNSON & JOHNSON DEL ECUADOR S.A.

01/2011 n.a. n.a. n.a. EC

123.

JOHNSON & JOHNSON DEL PERU S.A.

01/2011 n.a. n.a. n.a. PE

124.

JOHNSON & JOHNSON DO BRASIL INDUSTRIA E COMERCIO DE PRODUTOS PARA SAUDE LTDA

01/2011 n.a. n.a. n.a. BR

125.

JOHNSON & JOHNSON EGÉSZSÉGÜGYI ÉS BABAÁPOLÁSI TERMÉKEKET GYÁRTÓ ÉS FORGALMAZÓ KORLÁTOLT FELELOSSÉGU

01/2011 38,000 19,000 151 HU 4645

126.

JOHNSON & JOHNSON EUROPEAN TREASURY COMPANY

01/2011



dateOp. rev.

£'000sTot. assets


areaNACE

Rev. 2.0128.

JOHNSON & JOHNSON FINANCE LIMITED

01/2011 11,308 94,780 7 GB SL5 7739

129.

JOHNSON & JOHNSON FINANCIAL SERVICES GMBH

01/2011 38,000 115,000 4 DE 7729

130.

JOHNSON & JOHNSON GESELLSCHAFT M.B.H.

01/2011 n.a. n.a. 50 AT 4645

131.

JOHNSON & JOHNSON GMBH

01/2011 141,000 141,000 611 DE

131.1.

MCNEIL CONSUMER HEALTHCARE GMBH

04/2012 66,000 27,000 n.a. DE 2042

132.

JOHNSON & JOHNSON HEMISPHERICA, S A

01/2011 5,000 n.a. 66 US 4645

133.

JOHNSON & JOHNSON INC 01/2011 n.a. n.a. n.a. CA134.

JOHNSON & JOHNSON INDUSTRIAL LTDA.

01/2011 n.a. n.a. 1,200 BR 1722

135.

JOHNSON & JOHNSON INTERNATIONAL FINANCIAL SERVICES COMPANY

01/2011



dateOp. rev.

£'000sTot. assets


areaNACE

Rev. 2.0154.4.

ÅMIC AB 03/2012 3,000 9,000 34 SE 7211

154.4.1. ÅMIC PRODUCTION AB 03/2012



dateOp. rev.

£'000sTot. assets


areaNACE

Rev. 2.0176.

JOM PHARMACEUTICALS SERVICES INC

01/2011 n.a. n.a. n.a. US

177.

LATAM INTERNATIONAL INVESTMENT COMPANY

01/2011 n.a. 728,000 n.a. IE 6499

178.

LATAM PROPERTIES HOLDINGS

01/2011 n.a. 700,000 n.a. IE 6499

179.

LIFESCAN CANADA LTD 01/2011 10,000 n.a. 100 CA 4690180.

LIFESCAN LLC 01/2011 n.a. n.a. n.a. US

181.

LIFESCAN SCOTLAND LIMITED

01/2011 168,148 240,000 1,138 GB IV2 8690

182.

LUMEND, INC 01/2011 n.a. n.a. n.a. US183.

MCNEIL AB 01/2011 133,000 155,000 756 SE 2120

183.1.

BACKSVALAN 2 AB 03/2012 n.a. n.a. n.a. SE183.2.

FR BACKSVALAN 6 HANDELSBOLAG

03/2012 n.a. n.a. n.a. SE 6820

184.

MCNEIL CONSUMER HEALTHCARE GMBH

01/2011 66,000 27,000 n.a. DE 2042

185.

MCNEIL CONSUMER HEALTHCARE LATIN AMERICA LLC

01/2011 n.a. n.a. n.a. US

186.

MCNEIL DENMARK APS 01/2011 31,000 13,000 24 DK 4646187.

MCNEIL ESBJERG APS 01/2011 n.a. 1,000 n.a. DK 1089

188.

MCNEIL GMBH & CO. OHG 01/2011 52,000 31,000 79 DE189.

MCNEIL HEALTHCARE (UK) LIMITED

01/2011 225,938 161,250 n.a. GB KT20 4646

190.

MCNEIL LA LLC 01/2011 n.a. n.a. n.a. US191.

MCNEIL MANUFACTURING PTY LTD

01/2011 n.a. n.a. n.a. AU

192.

MCNEIL NUTRITIONALS LLC

01/2011 n.a. n.a. n.a. US

193.

MCNEIL PRODUCTS LIMITED

01/2011 n.a. 49,957 n.a. GB SL6 4646

194.

MCNEIL SWEDEN AB 01/2011 100,000 27,000 102 SE 4646195.

MEDOS SÀRL 01/2011 23,000 n.a. 700 CH 3250

196.

MENTOR MEDICAL SYSTEMS C.V.

01/2011 n.a. n.a. n.a. NL 4646

197.

MENTOR MINNESOTA INC 01/2011 n.a. n.a. n.a. US198.

MENTOR TEXAS LP 01/2011 13,000 n.a. 350 US 3250

199.

MICRUS ENDOVASCULAR CORPORATION

01/2011 56,000 49,000 307 US 3250

199.1.

MICRUS DESIGN TECHNOLOGY

06/2011 3,000 n.a. 51 US 3250

200.

MIDDLESEX ASSURANCE COMPANY LIMITED

01/2011 n.a. n.a. n.a. US

201.

NEUTROGENA CORPORATION

01/2011 56,000 n.a. 700 US 2042

202.

NITINOL DEVELOPMENT CORPORATION

01/2011 12,000 n.a. 130 US 2670

203.

NORAMCO, INC. 01/2011 17,000 n.a. 150 US 2120204.

OMJ MANUFACTURING 01/2011 n.a. n.a. n.a. IE 8299

205.

OMJ PR HOLDINGS 01/2011 n.a. n.a. n.a. IE 7010206.

OMRIX BIOPHARMACEUTICALS

01/2011 5,000 19,000 1 BE 4646

206.1.

BIOPEX LTD 12/2009 n.a. n.a. n.a. IL206.2.

OMRIX BIOPHARMACEUTICALS GMBH

12/2009 n.a.



dateOp. rev.

£'000sTot. assets


areaNACE

Rev. 2.0211.

ORTHO-CLINICAL DIAGNOSTICS

01/2011 172,172 181,321 496 GB HP12 2110

212.

ORTHO-CLINICAL DIAGNOSTICS GMBH

01/2011 60,000 56,000 210 DE 3250

213.

ORTHO-CLINICAL DIAGNOSTICS K.K.

01/2011 n.a. n.a. n.a. JP

214.

ORTHO-CLINICAL DIAGNOSTICS, INC.

01/2011 1,000 n.a. 9 US 3250

215.

ORTHO-MCNEIL FINANCE CO

01/2011 n.a. n.a. n.a. US

216.

ORTHOCLINICAL DIAGNOSTICS FRANCE

01/2011 415,000 157,000 226 FR 4646

217.

PATRIOT PHARMACEUTICALS, LLC

01/2011 1,000 n.a. 7 US 2120

218.

PT JOHNSON & JOHNSON INDONESIA

01/2011 n.a. n.a. n.a. ID

219.

RESPIVERT LTD. 01/2011 8,804 7,887 10 GB SW7 7219220.

RUTAN REALTY LLC 01/2011 n.a. n.a. n.a. US

221.

SCIOS INC 01/2011 43,000 n.a. 777 US 2120222.

SHANGHAI JOHNSON & JOHNSON LTD.

01/2011 23,000 19,000 286 CN 3250

223.

SHANGHAI JOHNSON & JOHNSON PHARMACEUTICALS, LTD

01/2011 n.a. n.a. n.a. CN

224.

SURGRX, INC. 01/2011 1,000 n.a. 14 US 3250225.

TASMANIAN ALKALOIDS PTY LIMITED

01/2011 n.a. n.a. n.a. AU

226.

TERAMED CORPORATION 01/2011 n.a. n.a. n.a. US227.

THE TYLENOL COMPANY 01/2011 n.a. n.a. n.a. US

228.

THERAKOS, INC. 01/2011 n.a. n.a. n.a. US229.

THERAPEUTIC DISCOVERY CORPORATION

01/2011 n.a. n.a. n.a. US

230.

TURNBUCKLE INVESTMENT COMPANY

01/2011 n.a. n.a. n.a. IE 6612

231.

VANIA EXPANSION 01/2011 7,000 66,000 50 FR 4646232.

VERIDEX, LLC 01/2011 4,000 n.a. 100 US 7022

233.

XIAN-JANSSEN PHARMACEUTICAL

01/2011 n.a. n.a. n.a. CN

234.

""JOHNSON & JOHNSON AB LATVIJAS FILIALE""

02/2012 5,000 n.a. 18 LV 4646

235.

CORDIS CORPORATION 11/2011 114,000 n.a. 2,079 US 3250235.1.

BIOSENSE WEBSTER INC. 10/2011 29,000 n.a. 525 US 2660

235.2.

CONOR MEDSYSTEMS, LLC

07/2011 13,000 n.a. 180 US 2660

235.3.

CORDIS DE MÉXICO, S.A. DE C.V.

07/2011 n.a. n.a. 2,000 MX 4690

235.4.

CORDIS ENDOVASCULAR SYSTEMS, INC

02/2012



dateOp. rev.

£'000sTot. assets


areaNACE

Rev. 2.0240.3.1. ETHICON LLC 04/2012 n.a. n.a. n.a. US 3250240.4.

OMRIX BIOPHARMACEUTICALS, INC.

01/2012 12,000 n.a. 212 US 2120

241.

HEALTHMEDIA, INC. 11/2011 4,000 n.a. 55 US 7022242.

HUMAN PERFORMANCE INSTITUTE, INC.

03/2012 - - - US 9329

243.

JANSSEN BIOLOGICS, LLC 02/2012 19,000 n.a. 200 US 2120244.

JANSSEN CILAG S A 11/2010 60,000 28,000 n.a. CO 4645

245.

JANSSEN CILAG, S.A. DE C.V.

10/2011 n.a. n.a. 1,000 MX 2110

246.

JANSSEN DIAGNOSTICS, INC.

12/2011 1,000 n.a. 75 US 4645

247.

JANSSEN ORTHO LLC 08/2011



dateOp. rev.

£'000sTot. assets


areaNACE

Rev. 2.0261.4.

JOHNSON Y JOHNSON DE COLOMBIA S A

07/2011 232,000 161,000 650 CO

261.5.

ORTHO CLINICAL DIAGNOSTICS K.K.

01/2011 123,000 n.a. n.a. JP 4645

262.

JOHNSON & JOHNSON JAPAN INC

10/2011


Controlling shareholders

BvD Independence Indicator: CFor this company the Global Ultimate Owner couldn’t be defined (due to mutual ownerships or equal percentages of ownership going upwards in the path). Shareholders

BvD Independence Indicator: C The companies underlined and displayed in grey are available on Mint Global. Shareholder name Direct

(%)Total(%)

Source date

Op. rev.£'000s

Tot. assets£'000s

Employees Country Postcode area

1. JJHC - n.a. 01/2012 n.a. n.a. 0 n.a.2. JOHNSON & JOHNSON - n.a. 01/2012 42,061,000 73,504,000 117,900 US * : For an insurance company the corresponding value is the Gross Premium Written and for a bank it is the Operating Income (memo) Ownership tree

JOHNSON & JOHNSON US221024240Turnover 42,061,000 £'000sNr. empl.: 117,900Subsidiaries: 293Shareholders: 101

JANSSEN-CILAG LIMITED GB01027904Turnover 271,117 £'000sNr. empl.: 793Subsidiaries: 0Shareholders: 2

JJHC YY*1500368988Turnover n.a.Nr. empl.: 0Subsidiaries: 1Shareholders: 0

JOHNSON & JOHNSON US221024240Turnover 42,061,000 £'000sNr. empl.: 117,900Subsidiaries: 293Shareholders: 101

n.a. n.a.

Auditors & advisors

Auditor(s)PRICEWATERHOUSECOOPERS LLP Banker(s)THE ROYAL BANK OF SCOTLAND PLC Original Documents

2012 Date Document Pages07/02/2012 Change in Director or Secretary - CH01 207/02/2012 Change in Director or Secretary - CH03 110/01/2012 Annual Return - AR01 4 2011 Date Document Pages22/09/2011 Change in Director or Secretary - AP01 2



Original Documents01/07/2011 Change in Director or Secretary - TM01 110/01/2011 Annual Return - AR01 502/01/2011 Annual Accounts - AA 32 2010 Date Document Pages27/01/2010 Change in Director or Secretary - CH01 227/01/2010 Change in Director or Secretary - CH01 215/01/2010 Change in Director or Secretary - AP01 210/01/2010 Annual Return - AR01 503/01/2010 Annual Accounts - AA 31 2009 Date Document Pages24/12/2009 Change in Director or Secretary - TM01 128/01/2009 Change in Director or Secretary - 288a 215/01/2009 Change in Director or Secretary - 288b 110/01/2009 Annual Return - 363a 4 2008 Date Document Pages28/12/2008 Annual Accounts - AA 3131/01/2008 Change in Director or Secretary - 288c 131/01/2008 Change in Director or Secretary - 288c 131/01/2008 Change in Director or Secretary - 288c 131/01/2008 Change in Director or Secretary - 288c 110/01/2008 Annual Return - 363a 3 2007 Date Document Pages30/12/2007 Annual Accounts - AA 3010/01/2007 Annual Return - 363a 2 2006 Date Document Pages31/12/2006 Annual Accounts - AA 2610/01/2006 Annual Return - 363 101/01/2006 Annual Accounts - AA 22 2005 Date Document Pages02/01/2005 Annual Accounts - acc
